Merge Therapeutics

Merge Therapeutics is a venture-backed biotechnology company developing dual-depleting macrophage engager antibodies for the treatment of immune-mediated diseases. The company is building first-in-class multispecific antibody therapies designed to shift the treatment paradigm for immunology and inflammation indications by simultaneously depleting pathogenic cell populations. It was co-founded by CEO Lauren Gehman, a 2025 Termeer Fellow, who is based in Mill Valley, California. Roche Venture Fund lists Merge Therapeutics in its venture portfolio. The company's website is a placeholder marked "coming soon" and no priced financing round has been publicly disclosed.